NCT04796441 is a NA clinical trial of CAR-γδT in AML, sponsored by Hebei Senlang Biotechnology Inc., Ltd..

Who is sponsoring NCT04796441?

NCT04796441 is sponsored by Hebei Senlang Biotechnology Inc., Ltd..

What drugs are being tested in NCT04796441?

Interventions in NCT04796441: CAR-γδT.

Is NCT04796441 still recruiting?

NCT04796441 is currently status unknown. Last updated 12 March 2021.

Last reviewed 2021-03-12 · How we verify

NCT04796441

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study of Universal CAR-γδT Cell Injection in the Treatment of Patients With Relapsed AML After Transplantation

Status unknown NA Last updated 12 March 2021

What this trial tests

NA trial testing CAR-γδT in AML in 20 participants. Status unknown.

Timeline

16 December 2020

Primary endpoint
16 December 2021

16 February 2022

Quick facts

Lead sponsor	Hebei Senlang Biotechnology Inc., Ltd.
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	16 December 2020
Primary completion	16 December 2021
Estimated completion	16 February 2022
Sites	1 location across China

Drugs / interventions tested

CAR-γδT

Conditions studied

AML — all drugs for AML →

Sponsor

Hebei Senlang Biotechnology Inc., Ltd. — full company profile →

Who can join

Adults 2 to 65, any sex, with AML. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open single-arm clinical study aimed at evaluating the efficacy and safety of universal γδT cell injection in the treatment of patients with relapsed AML after transplantation

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Challenges and new technologies in adoptive cell therapy.
Zhang P, Zhang G, Wan X. · · 2023 · cited 153× · PMID 37596653 · DOI 10.1186/s13045-023-01492-8
CAR γδ T cells for cancer immunotherapy. Is the field more yellow than green?
Ganapathy T, Radhakrishnan R, Sakshi S, Martin S. · · 2023 · cited 42× · PMID 35960333 · DOI 10.1007/s00262-022-03260-y
A close look at current γδ T-cell immunotherapy.
Ma L, Feng Y, Zhou Z. · · 2023 · cited 35× · PMID 37063836 · DOI 10.3389/fimmu.2023.1140623
Recent updates on allogeneic CAR-T cells in hematological malignancies.
Mansoori S, Noei A, Maali A, Seyed-Motahari SS, et al · · 2024 · cited 34× · PMID 39227937 · DOI 10.1186/s12935-024-03479-y
Engineering γδ T Cells: Recognizing and Activating on Their Own Way.
Dong R, Zhang Y, Xiao H, Zeng X. · · 2022 · cited 29× · PMID 35603176 · DOI 10.3389/fimmu.2022.889051
New cell sources for CAR-based immunotherapy.
Mazinani M, Rahbarizadeh F. · · 2023 · cited 25× · PMID 37147740 · DOI 10.1186/s40364-023-00482-9
Strategies to Improve the Antitumor Effect of γδ T Cell Immunotherapy for Clinical Application.
Miyashita M, Shimizu T, Ashihara E, Ukimura O. · · 2021 · cited 24× · PMID 34445615 · DOI 10.3390/ijms22168910
Targets for chimeric antigen receptor T-cell therapy of acute myeloid leukemia.
Schorr C, Perna F. · · 2022 · cited 21× · PMID 36605213 · DOI 10.3389/fimmu.2022.1085978

Verify or expand the search:

Other recruiting trials for AML

Currently open trials in the same condition.

NCT06611839 — Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML · Phase 1, PHASE2 · recruiting
NCT07163728 — Leptin: A Marker for AML Chemo-Sensitivity · recruiting
NCT06973668 — A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophospham · Phase 2 · recruiting
NCT07126782 — The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT · EARLY_PHASE1 · recruiting
NCT06717958 — Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute M · Phase 2 · recruiting

Other Hebei Senlang Biotechnology Inc., Ltd. trials

Trials by the same sponsor.

NCT07435779 — Autologous CAR-T Cell Therapy for Refractory and Relapsing Ulcerative Colitis: A Single-Center Exploratory Study · EARLY_PHASE1 · recruiting
NCT07421856 — Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial. · Phase 1, PHASE2 · not yet recruiting
NCT07244380 — Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL. · Phase 2 · not yet recruiting
NCT07161193 — Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases · Phase 1, PHASE2 · not yet recruiting
NCT07244406 — Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04796441 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hebei Senlang Biotechnology Inc., Ltd.
Last refreshed: 12 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04796441.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing